Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1162499, 1107188)
Received: 4 November 2020
Accepted: 21 October 2021
First Online: 11 November 2021
: T.S.P.H. received funding from Mesoblast Ltd and Regeneus Ltd outside of this work. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. N.D.H. and J.R. are founders and shareholders of oNKo-Innate Pty. Ltd, a discovery stage biotechnology company focussed on immuno-oncology, not related to this work. The remaining authors declare no competing interests.